Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-11-28
2002-07-23
Rotman, Alan L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S307000, C514S310000, C514S311000, C514S314000, C546S112000, C546S133000, C546S135000, C546S139000
Reexamination Certificate
active
06423723
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to non-peptidic amino derivatives, their therapeutic use, as well as pharmaceutical compositions comprising these derivatives. In particular, the invention relates to cyclic and acyclic alpha- and beta-aminocarboxamides, more particularly to tetrahydroisoquinolinecarboxamides, piperidinecarboxamides, pyrrolidinecarboxamides, and 2-amino-3-carboxamidopyridine derivatives. The compounds of the invention possess activity as Follicle Stimulating Hormone (FSH) agonists and are useful in the treatment of infertility.
2. Summary of the Related Art
Annually in the U.S. there are 2.4 million couples experiencing infertility that are potential candidates for treatment. Follicle stimulating hormone, either extracted from urine or produced by recombinant DNA technology, is a parenterally-administered protein product used by specialists for ovulation induction (OI) and for controlled ovarial hyperstimulation (COH). Whereas OI is directed at achieving a single follicle to ovulate, COH is directed at harvesting multiple oocytes for use in various in vitro assisted reproductive technologies (e.g., for in vitro fertilization). Clinical use of preparations containing FSH began in the 1960's.
Follicle stimulating hormone (FSH) is a pituitary-derived heterodimeric glycoprotein hormone that shares structural similarities with luteinizing hormone (LH) and thyroid stimulating hormone (TSH), both of which are also produced in the pituitary gland, and chorionic gonadotropin (CG), which is produced in the placenta The hormones are relatively large (28-38 kilodaltons) and are composed of a common a subunit non-covalently bound to a distinct &bgr; subunit that confers receptor binding specificity.
The cellular receptors for these hormones are known to be members of the G protein-coupled class of membrane-bound receptors, which when activated stimulate an increase in the activity of adenylyl cyclase. This results in an increase in the level of the intracellular second messenger adenosine 3′, 5′-monophosphate (cAMP), which in turn causes increased steroid synthesis and secretion. Hydropathicity plots of the amino acid sequences of these receptors reveal three general domains: (1) a hydrophilic amino-terminal region, considered to be the amino-terminal extracellular domain, (2) seven hydrophobic segments of membrane-spanning length, considered to be the transmembrane domain, and (3) a carboxy-terminal region that contains potential phosphorylation sites (serine, threonine, and tyrosine residues), considered to be the carboxy-terminal intracellular or cytoplasmic domain. The glycoprotein hormone receptor family is distinguished from other G protein-coupled receptors, such as the &bgr;2-adrenergic, rhodopsin, and substance K receptors, by the large size of the hydrophilic amino-terminal domain, which is involved in hormone binding.
The FSH receptor is expressed on testicular Sertoli cells and ovarian granulosa cells. While there has been a recognized need for providing essentially pure human FSH receptor, purification of naturally derived preparations is not practical and would likely be insufficient to permit determination of the amino acid sequence. Recently, one group has cloned the cDNA encoding the rat FSH receptor, deduced the amino acid sequence, and expressed it in mammalian cells (Sprengel,
Mol Endocrinol
4:525 (1990)). Another group, attempting to clone the TSH receptor, apparently also cloned and identified a portion of the transmembrane region of the human FSH receptor (Parmentier,
Science
246:1620 (1989)).
Use of FSH is limited by its high cost, lack of oral dosing, and need of extensive monitoring by specialist physicians. Hence, identification of a non-peptidic small molecule substitute for FSH that could potentially be developed for oral administration is desirable.
SUMMARY OF THE INVENTION
We have now found non-peptidic compounds for the treatment of infertility that mimic the action of FSH. Such compounds have superior convenience of use compared to FSH due to their oral bioavailability. They are suitable for prescription by a Ob/Gyn, require minimal supervision, and have substantially lower costs compared to FSH treatment.
REFERENCES:
patent: 3947569 (1976-03-01), Immer et al.
patent: 5071823 (1991-12-01), Kolar et al.
Sprengel et al.,Mol. Endocrinol. 4:525-530 (1990).
Parmentier et al.,Science, 246: 1620-1622 (1989).
Cassidenti et al.,Hum. Reprod. vol. 7, pp. 344-348 (1992).
Breckwoldt et al.,Fert. Steril. vol. 22, No. 7, pp. 451-455 (1971).
Diedrich et al.,Hum. Reprod. vol. 3, No. 1, pp. 39-44 (1988).
Kelton et al.,Molecular and Cellular Endocrinology, 89:141-151 (1992).
Dahl et al.,Methods Enzymol., 168:414-423 (1989).
Buckler David
El Tayer Nabil
Magar Sharad
Reddy Adulla
Applied Research Systems ARS Holding N. A.
Desai Rita
McDonnell & Boehnen Hulbert & Berghoff
Rotman Alan L.
LandOfFree
FSH mimetics for the treatment of infertility does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with FSH mimetics for the treatment of infertility, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and FSH mimetics for the treatment of infertility will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2853714